Raymond James Reiterates Market Perform Rating on Sage Therapeutics (SAGE), Sees Limited Upside to Stock Despite Strong zuranolone Data
Tweet Send to a Friend
Raymond James analyst Danielle Brill reiterated a Market Perform rating on Sage Therapeutics (NASDAQ: SAGE), following the company's announcement of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
